Toll-Like receptor 3-mediated interferon-ß production is suppressed by oncostatin m and a broader epithelial-mesenchymal transition program
Background: Patients with Triple Negative Breast Cancer (TNBC) currently lack targeted therapies, and consequently face higher mortality rates when compared to patients with other breast cancer subtypes. The tumor microenvironment (TME) cytokine Oncostatin M (OSM) reprograms TNBC cells to a more stem-like/mesenchymal state, conferring aggressive cancer cell properties such as enhanced migration and invasion, increased tumor-initiating capacity, and intrinsic resistance to the current standards of care. In contrast to OSM, Interferon-ß (IFN-ß) promotes a more differentiated, epithelial cell phenotype in addition to its role as an activator of anti-tumor immunity. Importantly, OSM suppresses the production of IFN-ß, although the mechanism of IFN-ß suppression has not yet been elucidated. Methods: IFN-ß production and downstream autocrine signaling were assessed via quantitative real-time PCR (qRT-PCR) and Western blotting in TNBC cells following exposure to OSM. RNA-sequencing (RNA-seq) was used to assess an IFN-ß metagene signature, and to assess the expression of innate immune sensors, which are upstream activators of IFN-ß. Cell migration was assessed using an in vitro chemotaxis assay. Additionally, TNBC cells were exposed to TGF-ß1, Snail, and Zeb1, and IFN-ß production and downstream autocrine signaling were assessed via RNA-seq, qRT-PCR, and Western blotting. Results: Here, we identify the repression of Toll-like Receptor 3 (TLR3), an innate immune sensor, as the key molecular event linking OSM signaling and the repression of IFN-ß transcription, production, and autocrine IFN signaling. Moreover, we demonstrate that additional epithelial-mesenchymal transition (EMT)-inducing factors, such as TGF-ß1, Snail, and Zeb1, similarly suppress TLR3-mediated IFN-ß production and signaling. Conclusions: Our findings provide a novel insight into the regulation of TLR3 and IFN-ß production in TNBC cells, which are known indicators of treatment responses to DNA-damaging therapies. Furthermore, strategies to stimulate TLR3 in order to increase IFN-ß within the TME may be ineffective in stem-like/mesenchymal cells, as TLR3 is strongly repressed. Rather, we propose that therapies targeting OSM or OSM receptor (OSMR) would reverse the stem-like/mesenchymal program and restore TLR3-mediated IFN-ß production within the TME, facilitating improved responses to current therapies. Overall design: RNA-seq profiling of BT-549 cells transduced with a lentivirus encoding either Oncostatin M (OSM), Transforming Growth Factor Beta 1 (TGF-B1), Snail (SNAI1), Zeb1 (ZEB1), or a an empty lentiviral vector (Vec).